文献速递自身炎症与 IgG4 相关病

斯蒂尔病中非感染性降钙素原升高的临床意义:巨噬细胞活化综合征的预测因子

Clinical significance of non-infectious procalcitonin elevation in Still's disease: a predictor of macrophage activation syndrome.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

这项回顾性研究纳入110例无感染的斯蒂尔病(SD)患者,以PCT 0.5 ng/ml为界分析其与临床特征的关系。结果显示SD患者PCT水平显著高于健康对照,MAS患者PCT升高程度接近感染组;PCT≥0.5组和PCTmax≥0.5组MAS风险在单因素分析中分别增加6.4倍和7.6倍,多因素分析中分别增加4.3倍和5.4倍。结论认为PCT可能是SD等自身炎症性疾病(AID)的潜在标志物,其升高可作为SD中MAS的独立预测因子。

要点

  • 110例无感染SD患者中,68%基线PCT<0.5 ng/ml,32%基线PCT≥0.5 ng/ml。
  • SD患者PCT水平显著高于健康对照,MAS患者PCT升高程度接近感染患者。
  • 单因素分析中PCT≥0.5组MAS风险增加6.4倍,PCTmax≥0.5组增加7.6倍。

核心结论

  • PCT可能是斯蒂尔病等自身炎症性疾病的潜在标志物,即使没有感染。
  • PCT水平升高可能是斯蒂尔病中巨噬细胞活化综合征的独立预测因子。

研究设计与样本

  • 回顾性研究纳入110例无感染且具备PCT数据的斯蒂尔病患者。
  • 对照组包括确诊血流感染患者和年龄、性别匹配的健康对照。
  • 以PCT 0.5 ng/ml为切点,按基线和最大值分组评估临床及实验室指标。

主要发现

  • 110例SD患者中,75例(68%)基线PCT<0.5 ng/ml,35例(32%)基线PCT≥0.5 ng/ml。
  • 63例(57.3%)PCTmax<0.5 ng/ml,47例(42.7%)PCTmax≥0.5 ng/ml。
  • SD患者PCT水平显著高于健康对照,MAS病例PCT升高程度接近感染病例。
  • MAS频率、较高的mPouchot评分和生物制剂DMARD(尤其阿那白滞素)使用增加与PCT升高相关。
  • 单因素分析中PCT≥0.5组MAS风险增加6.4倍,PCTmax≥0.5组增加7.6倍;多因素分析中分别增加4.3倍和5.4倍。

关键数值与推荐

  • PCT切点为0.5 ng/ml。
  • MAS风险在PCT≥0.5组单因素分析增加6.4倍,多因素分析增加4.3倍。
  • MAS风险在PCTmax≥0.5组单因素分析增加7.6倍,多因素分析增加5.4倍。

临床怎么用

  • 在无感染的斯蒂尔病患者中,PCT升高可提示MAS风险增加。
  • PCT水平可作为斯蒂尔病中评估MAS风险的潜在标志物。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Still's disease (SD) is an autoinflammatory disease (AID) that can lead to life-threatening macrophage activation syndrome (MAS). The role of procalcitonin (PCT) in AIDs remains unclear. This study aims to explore the relationship between non-infectious PCT elevation and clinical features of SD. METHODS: This retrospective study included patients with SD and absence of infection who had available PCT data. Control groups consisted of patients with confirmed bloodstream infections and age- and sex-matched healthy controls (HCs). A PCT cut-off of 0.5 ng/ml was used. Clinical and laboratory findings were evaluated based on baseline (PCT < 0.5 and PCT ≥ 0.5 groups) and maximum (PCTmax < 0.5 and PCTmax ≥ 0.5 groups) values. RESULTS: The study conducted with 110 patients with SD. Of these, 75 (68%) were in the PCT < 0.5 group and 35 (32%) were in the PCT ≥ 0.5 group, while 63 (57.3%) were in the PCTmax < 0.5 group and 47 (42.7%) were in the PCTmax ≥ 0.5 group. PCT levels were significantly higher in patients with SD compared with HCs and were nearly as elevated in MAS cases as in infection. Frequency of MAS, higher mPouchot scores and increased use of biologic DMARDs, particularly anakinra, were associated with elevated PCT. MAS risk increased 6.4-fold in the PCT ≥ 0.5 group and 7.6-fold in the PCTmax ≥ 0.5 group in univariate analysis, and 4.3-fold and 5.4-fold, respectively, in multivariate analysis. CONCLUSION: PCT may be a potential marker in AIDs such as SD, even in the absence of infection. Elevated PCT levels may serve as an independent predictor of MAS in SD.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bektas E, Uludogan BC, Firlatan Yazgan B, et al. Clinical significance of non-infectious procalcitonin elevation in Still's disease: a predictor of macrophage activation syndrome. Rheumatology (Oxford). 2026. PMID: 41160497. doi:10.1093/rheumatology/keaf575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。